To study whether FGFR3 is a potential target gene for AML therapy, MA-transduced pre-leukemia cells were constructed with CD117+ BM cells from FGFR3−/− and wild-type (WT) mice via infection of retrovirus (Supplementary Figures S1A,B). This evidence concerns the gene KIT and infection.